Monitor the company's ability to raise additional capital given the going concern warning and $6M market cap. Track SENTI-202 development milestones for potential CVR payments, though these are long-dated and highly contingent. Watch for Nasdaq compliance status and any further dilution.
Price Chart
Executive Summary
Senti Biosciences completed its merger with a Celadon Partners affiliate, divesting its operating subsidiary (Midco/Opco) and its lead asset SENTI-202. Public stockholders received no upfront cash; instead they received contingent value rights (CVRs) with an aggregate cap of $60M tied to SENTI-202 milestones. The company retained its Rett Syndrome and TIL programs, received a $2.5M capital infusion from the acquirer, and entered into a master consulting agreement with Opco for transitional services. The company also issued registration rights to the investor for the shares purchased in the capital infusion.
Key Financial Metrics
Key Facts
- Merger closed on October 21, 2026, with no upfront cash consideration to common stockholders.
- Stockholders received CVRs with aggregate cap of $60M tied to SENTI-202 milestones: $10M on BLA filing acceptance, $20M on FDA approval, $30M on cumulative net sales exceeding $200M.
- Company received $2.5M capital infusion from Parent (Celadon affiliate) at $0.342 per share, issuing 7,309,941 shares.
- Company forced exchange of $16.0M in convertible notes into 46,783,626 shares at $0.342 per share, causing massive dilution.
- Pro forma net loss for six months ended June 30, 2026 was $3.94M; for year ended December 31, 2025 was $15.52M.
- Company entered into a 12-month master consulting agreement with Opco for transitional services at estimated $26,750/month initially.
- Registration rights agreement filed for resale of shares issued in the $2.5M capital infusion.
- Company has going concern uncertainty and may not maintain operations starting as early as Q4 2026 without additional capital.
- Market cap is $6M; the $2.5M capital infusion represents ~42% of pre-deal market cap.
Financial Impact
No upfront cash consideration; CVRs up to $60M contingent on SENTI-202 milestones. $2.5M capital infusion. $16.0M notes exchanged for 46.8M shares at $0.342/share. Pro forma net loss $3.94M (H1 2026) and $15.52M (FY 2025).
Risk Factors
- Going concern risk: company may not maintain operations past Q4 2026 without additional financing.
- Massive dilution: 46.8M shares from note exchange plus 7.3M from capital infusion, on a pre-deal share count of ~31M.
- CVRs are highly speculative: SENTI-202 is an early-stage cell therapy with no guarantee of regulatory approval or commercial success.
- Nasdaq delisting risk remains given low market cap and stock price.
- Reliance on Opco for transitional services under master consulting agreement creates operational dependency.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-040772 |
| Document: ef20084208_ex10-2.htm | 0001140361-26-040772 |
| Document: ef20084208_ex10-3.htm | 0001140361-26-040772 |
| Document: ef20084208_ex2-2.htm | 0001140361-26-040772 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.1926 | awaiting T+5 | — | $0.1867 (−3.06%) |
Oct 26, 2026 1d ago | 8-K | $0.1720 | awaiting T+5 | — | $0.1867 (−8.55%) |
Oct 13, 2026 14d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1867 (−22.47%) |
Oct 13, 2026 14d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1867 (+22.47%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1867 (+43.30%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1867 (+43.30%) |
Sep 22, 2026 5w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1867 (+40.84%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1867 (+38.99%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1867 (−43.87%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1867 (+43.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers